Arrowhead Pharmaceuticals (ARWR)
(Delayed Data from NSDQ)
$20.80 USD
-0.34 (-1.61%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.79 -0.01 (-0.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ARWR 20.80 -0.34(-1.61%)
Will ARWR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARWR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARWR
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
ARWR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ARWR
Arrowhead granted breakthrough therapy designation for plozasiran by FDA
Interesting ARWR Put And Call Options For October 18th
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from TD Cowen
Hold Rating on Arrowhead Pharmaceuticals Amid Promising Clinical Data and Upcoming Regulatory Hurdles
Wall Street Analysts Are Bullish on Top Healthcare Picks